Scatec ASA
Invitation to presentation of Scatec ASA’s third quarter results 2024
Invitation to presentation of Scatec ASA’s third quarter results 2024
Oslo, 21 October 2024: Scatec ASA will release its third quarter results and provide a status update of its strategy, on Friday 1 November 2024 at 07:00 am (CET).
A presentation of the results followed by a Q&A session will be held on the same day at 09:00 am at Scatec’s headquarters at Skøyen Atrium III (1st floor), Askekroken 11, 0277 Oslo. The presentation and the Q&A session can be followed through a live webcast from our website www.scatec.com, or Scatec webcast Q3 2024.
For further information, please contact:
For analysts and investors: Andreas Austrell, VP IR, andreas.austrell@scatec.com
For media: Meera Bhatia, SVP External Affairs & Communications, meera.bhatia@scatec.com
About Scatec
Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy in emerging markets. As a long-term player, we develop, build, own, and operate renewable energy plants, with 4.7 GW in operation and under construction across four continents today. We are committed to grow our renewable energy capacity, delivered by our passionate employees and partners who are driven by a common vision of ‘Improving our Future’. Scatec is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘SCATC’. To learn more, visit www.scatec.com or connect with us on LinkedIn.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zealand Pharma18.7.2025 18:30:00 CEST | Press release
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
SpringWorks Therapeutics, Inc.18.7.2025 17:30:40 CEST | Press release
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Photocat A/S18.7.2025 17:00:00 CEST | Press release
PHOTOCAT has today applied for a transfer of its trading venue from Nasdaq First North Growth Market to Spotlight Stock Market.
Golden Ocean Group Limited18.7.2025 16:30:00 CEST | Press release
GOGL – Notice of Special General Meeting
Kapitalforeningen SDG Invest18.7.2025 16:06:31 CEST | Pressemeddelelse
Kapitalforeningen SDG Invest - Opdateret prospekt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom